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Abstract 1 
 
Evidence suggests that the stress hormones glucocorticoids (GCs) can cause 2 
cognitive deficits and neurodegeneration. Previous studies have found GCs facilitate 3 
physiological synapse weakening, termed long-term depression (LTD), though the 4 
precise mechanisms underlying this are poorly understood. Here we show that GCs 5 
activate glycogen synthase kinase-3 (GSK-3), a kinase crucial to synapse 6 
weakening signals. Critically, this ultimately leads to phosphorylation of the 7 
microtubule associated protein tau, specifically at the serine 396 residue, and this is 8 
a causal factor in the GC-mediated impairment of synaptic function. These findings 9 
reveal the link between GCs and synapse weakening signals, and the potential for 10 
stress-induced priming of neurodegeneration. This could have important implications 11 
for our understanding of how stress can lead to neurodegenerative disease. 12 
Keywords: Glucocorticoids; Long-term potentiation; GSK-3; Tau13 
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1. Introduction 14 
Repeated and chronic stress can cause acceleration of brain ageing, memory 15 
deficits and various mental illnesses [1,2]. Rising levels of the stress hormone 16 
cortisol are strongly correlated with temporal lobe atrophy and cognitive deficits 17 
during ageing in humans [2]. These effects are prevalent in patients with 18 
hypercortisolism [3,4] and can even be mirrored in otherwise healthy individuals by 19 
repeated exposure to environmental stressors such as jet lag [5]. It has been 20 
reported that prolonged secretion of glucocorticoids (GCs) during chronic stress, or 21 
exogenous application of GCs, disrupts memory performance in both humans [6,7] 22 
and rodents [8-10]. Understanding the precise mechanisms underpinning how 23 
elevated-GCs cause both cognitive deficits and structural atrophy in the brain 24 
remains a major scientific challenge with numerous translational implications. 25 
Several rodent studies have demonstrated that stress and GCs inhibit long-term 26 
potentiation (LTP) but enhance long-term depression (LTD) [11,12]. Given the 27 
postulated role for these synaptic phenomena in learning and memory [13], it is likely 28 
that their dysregulation is central to the cognitive impairments induced by GCs. 29 
Although the activation of glucocorticoid receptors (GRs) triggers a wide variety of 30 
intracellular signals [14-16], the synaptic signalling pathways that underlie aberrant 31 
synapse weakening by GCs remain to be elucidated. 32 
Based on the aforementioned findings, one possibility is that GCs regulate the 33 
direction of plasticity and/or the fate of synapses via modulation of certain signalling 34 
pathways involved in LTD, or synapse weakening. A key molecule linking synapse 35 
weakening and disruption of LTP expression is glycogen synthase kinase-3 (GSK-3) 36 
[17]. Our previous studies also implicate caspase-3-induced cleavage of Akt1 as a 37 
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critical factor for the expression of physiological LTD [18], and suggest that it acts as 38 
an upstream regulator of GSK-3 to enhance LTD in amyloid-beta (Aβ)-mediated 39 
pathophysiological conditions [19]. Furthermore, GSK-3 orchestrates this synapse 40 
weakening mechanism through regulation of tau phosphorylation (pTau) [20,21]. 41 
Given the key role of aberrant pTau in the pathophysiology of Alzheimer’s disease 42 
and stress-mediated neurodegeneration [22-24], we hypothesise that GSK-3-43 
mediated signalling pathways leading to pTau could be a synapse weakening 44 
mechanism common to these diseased states. 45 
Here we provide evidence that GCs activate a synapse weakening signal pathway 46 
centred around the cleavage of Akt1 by caspase-3 and subsequent activation of 47 
GSK-3, which causes aberrant pTau and abolishes LTP expression in the rat 48 
hippocampus. We identify a single pTau residue (Ser396) as a critical downstream 49 
signal in this mechanism, resulting in GC-mediated aberrant synaptic weakening. 50 
These findings could provide further translation to our understanding of how GCs 51 
prime progressive neurodegeneration through aberrant functional plasticity in the 52 
hippocampus. 53 
2. Materials and Methods 54 
2.1. Animals 55 
Experiments involving animals were conducted in accordance with the UK Animals 56 
Scientific Procedures Act, 1986 and associated guidelines. All experimental 57 
protocols were approved by the University of Bristol Animal Welfare & Ethical 58 
Review Body. Male Wistar rats (Charles River, UK) were used to prepare 59 
organotypic (7-day-old rats) and acute hippocampal slices (4- to 5-week-old rats). 60 
Rats were housed four or five per cage, and were allowed access to water and food 61 
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ad libitum. The cages were maintained at a constant temperature (23 ± 1°C) and 62 
relative humidity (60 ± 10%) under a 14/10 hour light-dark cycle (lights on from 8:00 63 
A.M.).  64 
2.2. Electrophysiology 65 
2.2.1. Acute hippocampal slice field recording 66 
Animals were sacrificed from 9:00 - 10:00AM by cervical dislocation. Brains were 67 
quickly removed into ice-cold artificial cerebrospinal fluid (ACSF; 124mM NaCl, 3mM 68 
KCl, 26mM NaHCO3, 1.25mM NaH2PO4, 2mM CaCl2, 1mM MgSO4, 10mM D-69 
glucose, carbogenated with 95% O2 / 5% CO2). Hemispheres were separated with a 70 
midsagittal cut and hippocampi were micro-dissected from each intact hemisphere. 71 
Transverse hippocampal slices (400 µm) were cut using a Mcllwain tissue chopper 72 
(Mickle Laboratory Engineering) and allowed to recover in a submersion-type bath 73 
filled with ACSF for at least 60 minutes. Before recording, hippocampal slices were 74 
incubated in ACSF with pharmacological compounds at room temperature. Evoked 75 
field excitatory postsynaptic potentials (fEPSPs) were recorded in the CA1 region 76 
using glass electrodes containing NaCl (3 M). Stimulating electrodes placed in the 77 
subiculum and CA2 region (Schaffer collateral pathway). Stimuli were delivered 78 
alternately to the two electrodes at a baseline rate of 0.066 Hz. Stimulus intensity 79 
was set at 30-40% of saturating intensity. After 30 minutes of stable baseline, high-80 
frequency stimulation (2 × 100 pulses; 100 Hz, 30 s interval) was used for the LTP 81 
induction protocol. LTP was gauged as the change of fEPSP slope relative to the 82 
preconditioning baseline. Both control and experimental recordings were collected 83 
using slices prepared from the same animal. Analysis of control LTP data across all 84 
field recording experiments showed no significant difference between mean post-85 
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conditioning fEPSPs in slices prepared from different rats (one-way ANOVA, F(4,33) 86 
= 2.147, p = 0.097). Data were captured and analysed using LTP114j software. Data 87 
are expressed relative to a normalized baseline. For analyses, the baseline was 88 
defined as 5 points before tetanic stimulation and the post-conditioning time was set 89 
at 75-80 minutes following recording commencement. The difference between 90 
baseline and post-conditioning time-points was expressed as a percentage of 91 
baseline ± SEM, and was used to make comparisons between treatment groups. 92 
 
2.2.2. Hippocampal slice culture and biolistic transfection 93 
Organotypic slices were cultured based upon a method previously described by 94 
Stoppini et al. (1991) [25]. Briefly, rats were decapitated, and their brains rapidly 95 
removed and placed into ice-cold dissecting medium containing: 238 mM sucrose, 96 
2.5 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 5 mM MgCl2, 11 mM D-glucose, and 97 
1 mM CaCl2. Hippocampi were extracted, and transverse hippocampal slices (350 98 
μm thickness) were cut and placed upon sterile, semi-porous membranes. These 99 
were stored and maintained at the interface between air and culture medium 100 
(containing: 78.8% Mimimum Essential Medium, 20% heat-inactivated horse serum, 101 
30 mM HEPES, 26 mM D-glucose, 5.8 mM NaHCO3, 2 mM CaCl2, 2 mM MgSO4, 70 102 
μM ascorbic acid, 1 μg/ml insulin, pH 7.3 and 320 – 330 mOsm/kg) inside a 103 
humidified incubator at 35°C with a 5% CO2-enriched atmosphere. Culture medium 104 
was refreshed every 2 days, and slices were used for whole-cell recording at 6 – 8 105 
days in vitro (DIV).  106 
DNA-coated microcarriers for biolistic transfection of organotypic hippocampal slices 107 
were prepared based on previously described methods [26]. At DIV 3–5, neurons 108 
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were transfected with plasmids expressing shRNA against rat tau protein (OriGene 109 
Technologies). A mixture of four different tau shRNA constructs (1:1:1:1, in pGFP-V-110 
RS vector) was used for tau silencing. Phosphorylation-null (serine residues mutated 111 
to alanine) human tau constructs of the AT8 [S199, S202, threonine 205 (T205)] and 112 
PHF-1 (S396, S404) epitopes, in pCI-neo vectors, were kindly provided by Dr. A. 113 
Takashima (Department of Aging Neurobiology, National Center for Geriatrics and 114 
Gerontology, Obu, Japan). Individual mutations to the PHF-1 epitope (residues S396 115 
or S404) were generated by site-directed mutagenesis (Agilent Technologies) of 116 
2N4R human tau. Wild-type and triple mutant Akt1 (D108A/D119A/D462N) were 117 
generated as previously described [18]. 118 
 
2.2.3. Whole–cell patch clamp recording 119 
For whole-cell recordings from cultured organotypic slices, the recording chamber 120 
was perfused with a buffer solution containing 119 mM NaCl, 2.5 mM KCl, 4 mM 121 
CaCl2, 4 mM MgCl2, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM glucose, 0.02 mM 122 
picrotoxin, and 0.01 mM 2-chloroadenosine. The buffer solution was maintained at 123 
29–30°C and saturated with 95% O2/5% CO2. Recording electrodes (5–6 MΩ) 124 
containing CsMeSO4 filling solution (130 mM CsMeSO4, 8 mM NaCl, 4 mM Mg-ATP, 125 
0.3 mM Na-GTP, 0.5 mM EGTA, 10 mM HEPES, and 6 mM QX-314, pH 7.2–7.3 and 126 
270 –290 mOsm/kg) were used to voltage clamp CA1 pyramidal neurons. EPSCs 127 
were recorded at a holding voltage of −70 mV, and only cells that had an initial Rs 128 
(series resistance) < 20 MΩ that was maintained within 20% of that value from start 129 
to finish were included in final data analysis. To induce LTP, depolarization of the cell 130 
to 0 mV was paired with 200 pulses of 2 Hz stimulation to the Schaffer collateral 131 
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input. Analysis of control LTP data across all whole cell patch recording experiments 132 
showed no variation in interleaved control LTP levels over time and in different slices 133 
(one-way ANOVA, F(4,11) = 1.775, p = 0.230). The change in peak amplitude of the 134 
EPSC, relative to baseline, was used to assess the effects of these stimulation 135 
protocols on synaptic efficacy. For analysis purposes, the baseline was defined as 5 136 
points before 2 Hz stimulation and the post-conditioning time was set as the last 5 137 
points at the 40-minute time-point. The difference between baseline and post-138 
conditioning time-points was expressed as a percentage of baseline ± SEM, and was 139 
used to make comparisons between treatment groups.  140 
 
2.3. Western Blotting and Antibodies 141 
Hippocampal slices were collected and homogenised in lysis buffer (1% SDS, 142 
292mM sucrose, 2.6mM EDTA, 1:10 Protease Inhibitor Cocktail (Sigma Aldrich), 143 
1:100 Phosphatase Inhibitor Cocktail 3 (Sigma Aldrich)). 144 
For immunoblotting, primary antibodies were used at the following dilutions: anti-145 
phospho-GSK-3β Ser9 (rabbit polyclonal, Cell Signalling Technology, 1:500), anti-146 
GSK-3β (H-76) (rabbit polyclonal, Santa Cruz Biotechnology, 1:500), anti-phospho-147 
Akt1 Ser473 (rabbit polyclonal, Cell Signalling, 1:1000), anti-phospho-Akt1 Thr308 148 
(rabbit polyclonal, Cell Signalling, 1:1000), anti-Akt1 (rabbit polyclonal, Cell 149 
Signalling, 1:1000), anti-PHF-1 (mouse monoclonal, kindly provided by Dr. P. 150 
Davies, 1:1000), anti-phospho-Tau Ser396 (rabbit polyclonal, Life Technologies, 151 
1:1000), anti-phospho-Tau Ser404 (rabbit polyclonal, Life Technologies, 1:1000), 152 
anti-phospho-PHF-tau pSer202+Thr205 (AT8) (Mouse monoclonal, Thermo 153 
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Scientific, 1:1000), anti-Tau 5 (mouse monoclonal, Life Technologies, 1:1000), anti-154 
β-Actin (mouse monoclonal, Abcam, 1:10,000).  155 
Membranes were incubated in horseradish peroxidase–conjugated secondary 156 
antibodies at the following dilutions: anti-rabbit (goat polyclonal, Millipore, 1:5000), 157 
anti-mouse (goat polyclonal, Millipore, 1:5000), followed by imaging with the G:Box 158 
gel imaging system (Syngene) using the EZ-ECL detection system (Thermo 159 
Scientific Inc.). Optical densities of immunoreactive bands were measured using 160 
ImageJ software (NIH) and statistical analysis conducted with SigmaPlot (Systat 161 
Software, Inc., USA). Example blots were cropped around regions of interest for 162 
presentation in figures. For quantitative comparisons of treatment groups, optical 163 
densities for proteins of interest were normalized to loading-control protein levels and 164 
expressed relative to the average value from the control group. 165 
 
2.4. Akt1 kinase assay 166 
Akt1 activity was determined as described by the manufacturer’s instructions (Cell 167 
Signalling), with minor modifications. Acute hippocampal slices were washed with 168 
TBS and homogenised in IP buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1 % Triton X-169 
100, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM Na-Orthavanadate, 1X 170 
phosphatase inhibitors and 1X Protease inhibitors). Lysates were centrifuged at 171 
15,000 g for 15 minutes at 4°C and the supernatant transferred to fresh tubes. 172 
Immunoprecipitation of Akt1 was performed using 500 μg of lysate and incubated 173 
with 2 μg of Akt1 Ser473 antibody overnight at 4°C. Subsequently, 30 μl of washed 174 
Protein G agarose slurry was added and incubated at 4°C for 45 minutes with over-175 
end mixing. The beads were washed twice in IP buffer, followed by two washes in 176 
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NEB kinase buffer. The immobilised precipitated Akt1 was incubated in 40 µl kinase 177 
buffer containing 200 µM ATP and 1 µg of GSK3β fusion protein at 30°C for 30 178 
minutes. The reaction was stopped by addition of 20 µl of 3X sample buffer. The 179 
samples were vortexed and centrifuged prior to heating and protein separation by 180 
SDS-PAGE. 181 
 
2.5. Statistical analysis 182 
Where practically possible, experiments were performed blind to experimental 183 
condition. Results are presented as the mean ± standard error of the mean (SEM). 184 
Results were analysed using unpaired t-test for two independent groups or by one-185 
way ANOVAs with post-hoc Holm-Sidak analysis for multiple groups, as indicated in 186 
the results text and figure legends. p < 0.05 was considered statistically significant. N 187 
numbers represent samples from independent animals unless otherwise specified.  188 
 
3. Results 189 
3.1. GCs activate a synapse weakening pathway to inhibit LTP 190 
In acutely prepared dorsal hippocampal slices, corticosterone (CORT; 1 µM) 191 
application for 2 hours (Ctrl: 146.12 ± 2.9%; CORT: 114.33 ± 5.6%, unpaired t-test 192 
t(13) = 5.2, p < 0.001, Fig. 1a), or application of the synthetic glucocorticoid 193 
dexamethasone (DEX; 200 nM, 2 hours, Ctrl: 164.35 ± 4.5%; DEX: 133.92 ± 3.9%, 194 
unpaired t-test, t(12) = 4.9, p < 0.001, Fig. 1b), both inhibited LTP induction when 195 
compared to untreated slices. No effects of CORT treatment on basal properties of 196 
synaptic transmission were observed (Supplementary Fig. S1). Based on previous 197 
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studies [18-21], we hypothesised that GCs activate a caspase-3-Akt1-GSK-3 198 
signalling (CAG) cascade that induces aberrant expression of LTD and inhibits LTP. 199 
We therefore tested whether GC exposure impairs LTP via activation of this CAG 200 
cascade. Co-application of the GSK-3 inhibitor CT-99021 (1 µM) prevented the LTP 201 
impairment that was induced by CORT treatment alone (CORT: 114 ± 5.3%; 202 
CORT+CT-99021: 142.9 ± 3.8%, unpaired t-test, t(10) = 3.1, p = 0.0114, Fig. 1c), 203 
suggesting that GSK-3 activation is required for CORT-mediated inhibition of LTP. 204 
Furthermore, LTP impairment induced by CORT was prevented by the caspase 205 
inhibitor Z-DEVD-FMK (10 μM) but not by the non-active control peptide Z-FA-FMK 206 
(10 μM), supporting a role for caspase-3 upstream of GSK-3 activation in the 207 
aberrant modulation of synaptic plasticity (one-way ANOVA, F(3,22) = 8.85, p = 208 
0.003; Holm-Sidak post hoc test for CORT+Z-DEVD-FMK (149.7 ± 6.4%, p = 0.005) 209 
and CORT+Z-FA-FMK (120.7 ± 5.2%, p = 0.793) vs CORT (118.5 ± 5.8%), Fig. 1d). 210 
Indeed, the activation of GSK-3 was robustly induced by CORT treatment and was 211 
prevented by pre-treatment (30 min) and co-application of Z-DEVD-FMK (one-way 212 
ANOVA, F(3,36) = 14.41, p < 0.001; Holm-Sidak post hoc test for CORT (56.7 ± 213 
9.6%) vs CORT+Z-DEVD-FMK (89.1 ± 6.4%, p = 0.031), Fig. 1e). Z-FA-FMK had no 214 
effect on the CORT-induced activation of GSK-3β (CORT (56.7 ± 9.6%) vs CORT+Z-215 
FA-FMK (58.8 ± 7.9 %, p = 0.858, Fig. 1e) and neither Z-DEVD-FMK nor Z-FA-FMK 216 
altered the total expression level of GSK-3β (one-way ANOVA, F(3,39) = 0.09, p = 217 
0.96, Fig. 1e).  218 
We also utilized a previously characterised XIAP Bir 1,2 protein, which inhibits 219 
caspase-3 and 7 activation [18]. XIAP Bir 1,2 was biolistically transfected into 220 
neurons of cultured hippocampal slices. In this cultured slice model, cells exposed to 221 
CORT treatment (200 nM, 24 hours) exhibited impaired LTP when compared to 222 
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untreated cells (untreated: 160.1 ± 14.0%; CORT: 93.7  ± 15.2%, unpaired t-test t(8) 223 
= 3.2, p = 0.012, Fig. 1f). This effect was dependent upon the presence of the GR, 224 
such that CORT failed to block LTP in neurons transfected with GR shRNA when 225 
compared to untransfected cells (untransfected: 85.7 ± 12.5%; GR-shRNA 226 
transfected: 157.3  ± 24.9 %, unpaired t-test t(8) = 2.6, p = 0.033, Fig. 1g). CORT 227 
treatment did not inhibit LTP in XIAP Bir1,2 overexpressing cells when compared to 228 
untransfected cells (untransfected: 103.6 ± 20.8%; XIAP Bir1,2 transfected: 169.5 ± 229 
20.2%, unpaired t-test t(11) = 2.3, p = 0.044, Fig. 1h), indicating a requirement for 230 
caspase-3 / 7 activation for the inhibition of LTP by CORT. In line with our 231 
hypothesis, these results suggest that CORT induces both GSK-3 and caspase 232 
activation. 233 
 
3.2. GCs inhibit LTP via Akt1 regulation 234 
Since the mitochondrial permeability transition pore (mPTP) is important for the 235 
activation of caspases [27], we tested whether mPTP regulates CORT-induced LTP 236 
inhibition. The mPTP inhibitor TRO-19622 (25 μM) prevented both the CORT-237 
mediated activation of GSK-3β (one-way ANOVA, F(2,15) = 11.74, p = 0.003; Holm-238 
Sidak post hoc test for CORT+TRO-19622 (94.9 ± 6.9%, p = 0.010) vs CORT (69.7 239 
± 3.6%), Fig. 2a) and the inhibition of LTP (CORT: 114.3 ± 5.8%; CORT+TRO-240 
19622: 144.1 ± 2.2%, unpaired t-test t(11) = 6.5, p = 0.001, Fig. 2b). These results 241 
imply that aberrant regulation of mPTP activates caspase and GSK-3, which 242 
subsequently dysregulate LTP. Since caspase-3 can regulate GSK-3 through 243 
cleavage of Akt1 [18,19], we hypothesised that the observed caspase mediated 244 
upregulation of GSK-3 activity might be due to Akt1 cleavage and that this is a key 245 
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sequential step in the inhibition of LTP. Previous findings have shown that 246 
phosphorylation of Akt1 modulates its cleavage in a site–specific manner [28]. We 247 
therefore measured the phosphorylation of Akt1 at Thr308, a site correlated with 248 
Akt1 cleavage and activity [29]. We found that Thr308 phosphorylation was 249 
significantly reduced by CORT treatment (one-way ANOVA, F(3,20) = 10.13, p < 250 
0.001; Holm-Sidak post hoc test for CORT (42.2 ± 12.3%, p  = 0.024) vs control 251 
(100.0 ± 13.0%), Fig. 2c) and that this reduction was prevented by pre-treating slices 252 
with either Z-DEVD-FMK or the GR antagonist RU486 (500 nM), (CORT vs 253 
CORT+Z-DEVD-FMK (142.6 ± 17.5%, p < 0.001), CORT vs CORT+RU486 (114.7 ± 254 
8.9%, p = 0.005,Fig. 2c). The total expression of Akt1 was unaffected by CORT, Z-255 
DEVD-FMK or RU486 (one-way ANOVA, F(3,20) = 0.59, p = 0.632, Fig. 2c). This 256 
suggests that CORT inhibits Akt1 activity via caspase activation, and is a specific 257 
consequence of GR activation. To further validate the effect of CORT on Akt1 258 
activity, we used an in vitro kinase assay utilising immuno-precipitated Akt1 from 259 
control and CORT treated hippocampal slices and a GSK-3 fusion protein as a 260 
substrate to determine the activity of immobilised Akt1. We found that CORT 261 
treatment reduced Akt1 activity as observed by a significant decrease in 262 
phosphorylated GSKαβ at serine residues 21 and 9 (pGSKαβ Ser21/9) levels 263 
compared to control (control: 100.0 ± 8.44%; CORT: 73.9 ± 3.67%, unpaired t-test 264 
t(4) = 7.1, p = 0.002, Fig. 2d). We next aimed to determine whether caspase-3-265 
mediated Akt1 cleavage is important for the inhibition of LTP by CORT. To do this, 266 
we biolistically transfected mutant Akt1 protein (Akt1 triple mutant, resistant to 267 
cleavage by caspase-3[18]) into CA1 hippocampal neurons. CORT treatment did not 268 
impair LTP in cells transfected with the Akt1 triple mutant when compared to 269 
untransfected cells (untransfected: 104.9 ± 7.2%; Akt1 triple mutant transfected; 270 
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144.8 ± 13.5%, unpaired t-test t(9) = 2.5, p = 0.036, Fig. 2e) but inhibited LTP in cells 271 
transfected with wild-type Akt1 (untransfected: 117.4 ± 11.7.%; Akt1 wild-type: 107.4 272 
± 16.3%, unpaired t-test t(10) = 0.5, p = 0.628, Fig. 2f).  273 
3.3. GCs induce pTau specifically at the PHF-1 epitope 274 
Together, these results suggest that CORT-mediated LTP inhibition relies upon the 275 
cleavage of Akt1 by caspase-3 and this might be a critical step to further 276 
downstream signal cascades which ultimately execute functional synapse 277 
weakening. What remains to be shown, however, are the potential downstream 278 
substrates that mediate synaptic weakening and dysregulate LTP. GSK-3 is a well-279 
characterised kinase of the tau protein, governing the phosphorylation of tau (pTau) 280 
at multiple sites [30]. Interestingly, pTau at Ser396, one of the GSK-3 target sites 281 
closely associated with pathogenesis in AD [30], was recently revealed as necessary 282 
for LTD [21]. Given previous evidence showing increased pTau following stress [31], 283 
we postulated that CORT-induced activation of GSK-3, via upstream caspase-3-Akt1 284 
regulation, might culminate in greater pTau and thus aberrant modulation of synaptic 285 
plasticity. Therefore, we tested whether caspase, mPTP and GSK-3 activation are 286 
involved in CORT-mediated changes to pTau. CORT treatment significantly 287 
increased immunoreactivity with the PHF-1 antibody, which detects pTau at amino 288 
acids Ser396 and Ser404 (S396/404) (one-way ANOVA, F(3,20) = 4.83, p < 0.001; 289 
Holm-Sidak post hoc test for control (100.0 ± 16.0%) vs CORT (135.9 ± 7.9%, p = 290 
0.001, Fig. 3a), and this effect of CORT occurred in a caspase dependent manner 291 
(CORT vs CORT+Z-DEVD-FMK (90.4 ± 4.4%, p < 0.001, Fig. 3a). We also tested 292 
AT8, an antibody that detects alternate GSK-3 phosphorylation residues Ser-202 293 
and Thr-205, and found no change in phosphorylation at these sites (one-way 294 
ANOVA, F(3,20) = 0.43, p = 0.734, Fig. 3b). The CORT-mediated increase in PHF-1 295 
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immunoreactivity was also prevented by co-treatment with an inhibitor of the mPTP 296 
((one-way ANOVA, F(2,15) = 9.96, p < 0.001; Holm-Sidak post hoc test for control 297 
(100.0 ± 4.2%) vs CORT (139.7 ± 5.9%, p = 0.003), CORT vs CORT+TRO-19622 298 
(88.2 ± 10.0%, p < 0.001, Fig. 3c) or an inhibitor of GSK-3 (139.8 ± 8.0%) vs 299 
CORT+CT-99021 (104.1 ± 10.4%, p = 0.008, Fig. 3e). AT8 immunoreactivity was 300 
again unchanged in both cases (one-way ANOVA, F(2,15) = 0.58, p = 0.573, Fig. 301 
3D; one-way ANOVA, F(2,24) = 0.38, p = 0.69, Fig. 3f).These data show that CORT-302 
triggered signalling cascades drive an increase in pTau, specifically at residues of 303 
the PHF-1 epitope. 304 
 
3.4. CORT-induced inhibition of LTP is mediated by specific pTau at Ser396 305 
Based on previous findings that pTau is required for LTD induction as well as Aβ-306 
mediated LTP inhibition [21, 22], we were interested in determining whether CORT-307 
induced LTP inhibition is due to aberrant synapse weakening mediated through 308 
pTau. To test this, endogenous tau was first knocked down by rat tau small hairpin-309 
forming interference RNA (shRNA) in cultured hippocampal slices [21], allowing us to 310 
determine whether tau itself is critical to CORT-mediated LTP inhibition. Indeed, 311 
robust LTP was induced in rat tau shRNA transfected neurons, but not in 312 
untransfected neurons, that were treated with CORT (untransfected: 105.6 ± 17.9%; 313 
tau shRNA transfected: 162.9 ± 19.5%, unpaired t-test t(12) = 2.4, p = 0.032, Fig. 314 
4a). In addition, neurons where endogenous tau was replaced with S396/404 residue 315 
phospho-null human tau (S396/404A) readily exhibited LTP following treatment with 316 
CORT when compared to untransfected cells (untransfected: 100.1 ± 12.1%, 317 
S396/404A transfected: 145.5 ± 12.1%, unpaired t-test t(11) = 2.2, p = 0.040, Fig. 318 
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4b), indicating that tau and its phosphorylation are important for the effect of CORT 319 
on LTP. We next wanted to determine whether there was a selective requirement for 320 
phosphorylation at either of these sites within this mechanism. We therefore 321 
generated and transfected neurons with single phospho-null tau mutants in 322 
conjunction with rat tau shRNA. We found that, following CORT treatment, LTP was 323 
present in neurons expressing the S396A mutant (untransfected: 84.0± 9.9%; S396A 324 
transfected: 177.0 ± 30.4%, unpaired t-test t(11) = 2.7, p = 0.020, Fig. 4c) but not in 325 
neurons expressing the S404A form (untransfected: 101.9 ± 14.2 %; S404A 326 
transfected: 108.8± 17.6%, unpaired t-test t(8) = 0.3, p = 0.770, Fig. 4d). In contrast, 327 
neurons where endogenous tau was replaced with Ser199/202/Thr205 residue 328 
phospho-null human tau (S/T199/202/205A) were still sensitive to CORT-mediated 329 
inhibition of LTP (untransfected: 85.4 ± 13.0%; S/T199/202/205A transfected: 117.4 330 
± 11.7%, unpaired t-test t(9) = 1.8, p = 0.100, Fig. 4e). Together, these data suggest 331 
that pTau at the Ser396 residue is specifically required for CORT-induced inhibition 332 
of LTP. 333 
 
4. Discussion 334 
Our data are consistent with a serial synaptic weakening mechanism in which the 335 
activation of caspase-3 leads to cleavage of Akt1, removing the tonic inhibition of 336 
GSK-3, which subsequently increases pTau and causes inhibition of LTP. Caspase-337 
3, GSK-3 and pTau are all critically involved in LTD, and aberrant LTD expression by 338 
these molecules has been implicated in the pathophysiology of synapse weakening 339 
and neurodegeneration [18,19,21,32-35]. Interestingly, LTP induction can inhibit LTD 340 
signalling cascades [17] and, conversely, aberrant activation of LTD and/or synapse 341 
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weakening signalling cascades inhibits LTP expression [18,19]. This suggests that 342 
LTP and LTD signalling molecules are tightly regulated and are maintained in 343 
balance at basal states. A given stimuli (i.e., GCs), therefore, could tip this balance in 344 
favor of LTP or LTD by acting as a catalyst for signalling mechanisms associated 345 
with one or the other form of plasticity. Previous studies have demonstrated that the 346 
inhibition of aberrantly expressed LTD and synapse weakening signalling molecules 347 
restores LTP expression ordinarily inhibited in an Aβ neurotoxicity model [19,35]. 348 
Therefore, a compelling explanation for the data presented in this study is that GC-349 
activated synapse weakening signalling results in the inhibition of LTP.  350 
Given the numerous studies showing GC-facilitated LTD [11,12,14], there was 351 
significant scope for GCs activating key LTD/synapse weakening molecules. Among 352 
many of the LTD/synapse weakening molecules, we were specifically interested in 353 
GSK-3, considered pivotal in LTD expression and known to be involved in certain 354 
types of neurodegeneration [17,36]. Underlying our focus on GSK-3 were the 355 
previous observations broadly linking GCs with upregulated GSK-3 activity [31,37], 356 
findings which are consistent with the results presented here. A next important step 357 
will be to determine the mechanisms by which GCs can modulate GSK-3 activity. 358 
GCs activate caspase-3 in cultured rat hippocampal neurons [38] and activation of 359 
GR specifically is known to regulate this proapoptotic pathway [39]. Indeed, our 360 
TRO-19622 experiment data suggest that GCs regulate the proapoptotic mPTP and 361 
cytochrome c, and this may serve as a key step in the activation of GSK-3. We have 362 
previously suggested that caspase-3-mediated cleavage of Akt-1 is critical for the 363 
activation of GSK-3 by Aβ and aberrant expression of LTD in the hippocampus [18]. 364 
Furthermore, the constitutive inhibition of GSK-3 is primarily governed by the PI3K-365 
Akt signaling pathway [40], which is subject to GC regulation [15,16]. It has also 366 
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been suggested that GCs inhibit the canonical wingless (WNT) pathway through 367 
Dickkopf 1 (DKK1) [41], which can regulate GSK-3 activity [42]. Therefore, it is clear 368 
that signalling pathways converging on GSK-3 are indeed liable to modulation by 369 
GCs, and such events could serve as the means by which synapse weakening is 370 
induced by GCs. 371 
In the view of activation of GSK-3 by GCs, we hypothesised that the downstream 372 
signalling of GSK-3 would promote LTD and/or synapse weakening molecules. 373 
Given that GSK-3 is a typical tau kinase and our previous study suggested that tau is 374 
essential for LTD expression [20], this hypothesis was tested by knockdown of tau. 375 
As we recently found that tau phosphorylation by GSK-3 is a critical molecular step 376 
in LTD induction but has no role in LTP [21], we also showed that a specific 377 
phospho-null mutation of tau blocked GC-mediated inhibition of LTP. Growing 378 
evidence now links GC exposure with tau phosphorylation [31,38,43-46], though the 379 
significance of this had remained relatively under explored. Our study now strongly 380 
suggests that GC-mediated GSK-3 activation regulates aberrant tau phosphorylation 381 
and this causes inhibition of LTP. The real consequences of this could then be two-382 
fold; firstly, the dysregulation of synaptic function as a result of the synapse 383 
weakening pathway activation. Secondly, GC-induced tau phosphorylation per se 384 
could seed tauopathies. It remains to be determined, however, whether there is a 385 
specific role of membrane-bound-GRs or cytosolic GRs in activating these signalling 386 
pathways that mediate the inhibition of LTP by CORT. 387 
Of particular interest is our novel observation that specific phosphorylation of tau at 388 
Ser396 is central to GC-induced synapse weakening. Aside from the established role 389 
of this phosphorylation signal with physiological LTD [20,21], it is intriguing to note 390 
other studies linking the phosphorylation of tau at this residue with pathological 391 
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conditions. In particular, GCs have been shown to induce the accumulation of tau 392 
specifically phosphorylated at Ser396 within the synaptic compartment [47]. 393 
Furthermore, tau phosphorylated at Ser396 is accumulated in the synaptic 394 
compartment of Alzheimer’s disease and α-synucleinopathy brains and is considered 395 
to be one of the earliest cellular events associated with these pathologies [48,49]. 396 
Therefore, the GC-activated caspase-3-GSK-3-pTau signalling pathway may be a 397 
potential molecular mechanism of stress mediated synapse weakening that primes 398 
neurodegenerative and precedes cognitive decline onset. Control of such aberrant 399 
synapse weakening signals may therefore be a useful symptom modification strategy 400 
for improvement of cognitive impairments, such as in dementia.   401 
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Figure Legends 543 
Figure 1: Glucocorticoids impair LTP via caspase-mediated GSK-3 activation 544 
(a, b, c and d) Field recording in rat hippocampus CA1. Top: Example traces of 545 
fEPSPs from indicated timepoints. Bottom: Mean fEPSP slope shown as percentage 546 
of the established baseline. (a) LTP is inhibited by CORT treatment (n = 8).  (b) Bath 547 
application of DEX inhibits LTP (n = 6). (c) Treatment with CT-99021 prevents LTP 548 
impairment induced by CORT (n = 6). (d) Z-DEVD-FMK blocks impairment of LTP by 549 
CORT (n = 6), but scrambled peptide Z-FA-FMK does not (n = 6). Bath application of 550 
CORT and CT-99021, and delivery of tetanus (100Hz, 100 pulses) indicated by black 551 
rectangles. (e) Z-DEVD-FMK rescues the reduction of GSK-3 inhibitory 552 
phosphorylation caused by CORT treatment (n = 10), but Z-FA-FMK does not (n = 553 
10). Left: Cropped example blots showing immunoreactive bands from different 554 
treatment groups. Top Right: Quantification of changes in immunoreactivity of pS9 555 
GSK-3β normalised against total GSK-3β. Bottom Right: Levels of total GSK-3β 556 
normalised against β-actin loading control.  (f, g and h) Whole cell patch clamp 557 
recording in CA1 region of cultured hippocampal slices. Top: Example traces of 558 
EPSCs from indicated timepoints. Bottom: Mean peak EPSC shown as percentage 559 
of the established baseline. (f) CORT treatment blocks LTP induction (n = 5, control 560 
n = 5). (g) GR shRNA prevents CORT-induced LTP impairment (GR shRNA 561 
transfected n = 5, untransfected n = 5). (h) XIAP Bir1,2 prevents CORT-induced LTP 562 
impairment (XIAP Bir1,2 transfected n = 7, untransfected n = 6). All bars and circles 563 
represent the mean ± SEM.  Statistical significance was determined by one-way 564 
ANOVA and Holm-Sidak post hoc analysis indicated as *p < 0.05, **p < 0.01, ***p < 565 
0.001. 566 
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Figure 2: Caspase-mediated Akt1 cleavage is required for the inhibition of LTP 567 
by CORT 568 
 (a) TRO-19622 prevents the reduction of pS9GSK-3β caused by CORT treatment (n 569 
= 6). Left: Cropped example blots showing immunoreactive bands from different 570 
treatment groups. Top Right: Quantification of changes in immunoreactivity of pS9 571 
GSK-3β normalised against total GSK-3β. Bottom Right: Levels of total GSK-3β 572 
normalised against β-actin loading control. (b) TRO-19622 inhibits CORT-induced 573 
LTP impairment (n = 6). (c) Left: Cropped example blots showing immunoreactive 574 
bands from different treatment groups. Middle: Quantification of pAkt1(Thr308) 575 
immunoreactivity normalised to total Akt1. Right: Total Akt1 normalised to β-actin 576 
loading control. The reduction in Thr308 phosphorylation of Akt1 following CORT 577 
treatment (n = 6) was rescued by Z-DEVD-FMK (n = 6) and RU486 (n = 6). (d) 578 
CORT treatment reduces Akt1 activity as determined by a significant decrease in 579 
pGSKαβ Ser21/9 levels compared to control (n = 3). (e and f) Whole cell patch 580 
clamp recording in CA1 region of cultured hippocampal slices. Top: Example traces 581 
of EPSCs from indicated timepoints. Bottom: Mean peak EPSC shown as 582 
percentage of the established baseline. (e) CORT does not impair LTP in slices 583 
transfected with Akt1 triple mutant (Akt1 triple mutant transfected n = 6, 584 
untransfected n = 5), (f) whereas Akt1 wild-type has no effect on CORT-induced LTP 585 
impairment (Akt1 wild-type n = 7, untransfected n = 6). 2 Hz stimulation indicated by 586 
black rectangles. All bars and circles represent the mean ± SEM. Statistical 587 
significance was determined by one-way ANOVA and Holm-Sidak post hoc analysis 588 
and unpaired t-test indicated as *p < 0.05, **p < 0.01, ***p < 0.001. 589 
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Figure 3: Caspase, mPTP and GSK-3 activation regulate CORT-mediated 590 
changes to pTau 591 
Western blots showing changes in phosphorylation of tau. Left: Cropped example 592 
blots showing immunoreactive bands from different treatment groups. Right: 593 
Quantification of pTau antibody immunofluorescence normalised to total tau (Tau5). 594 
(a and b) pTau measured by PHF-1 is increased by CORT and rescued by Z-DEVD-595 
FMK, but not scrambled peptide Z-FA-FMK (n = 6). Immunoreactivity of AT8 is 596 
unchanged by any treatment (n = 6). (c and d) TRO-19622 also prevents the 597 
increase in PHF-1 immunoreactivity caused by CORT (n = 6), without affecting levels 598 
of AT8 (n = 6). (e and f) Additionally, CT-99021 blocks the increase in PHF-1 599 
immunoreactivity caused by CORT (n = 9), while AT8 immunoreactivity is not 600 
affected by CORT or CT-99021 (n = 9). All bars represent the mean ± SEM. 601 
Statistical significance was determined by one-way ANOVA and Holm-Sidak post 602 
hoc analysis indicated as *p < 0.05, **p < 0.01, ***p < 0.001. 603 
 
Figure 4: pTau at Ser396 is specifically required for CORT-induced inhibition of 604 
LTP 605 
Whole cell patch clamp recording in CA1 region of cultured hippocampal slices. Top: 606 
Example traces of EPSCs from indicated timepoints. Bottom: Mean peak EPSC 607 
shown as percentage of the established baseline. (a) LTP can still be induced after 608 
CORT treatment in neurons transfected with tau shRNA (tau shRNA n = 8, 609 
untransfected n = 6). (b) Neurons expressing the tau S396/404A mutant exhibited 610 
LTP after treatment with CORT (tau S396/404A transfected n = 8, untransfected n = 611 
5). (c) LTP can be induced after CORT treatment in neurons transfected with the 612 
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single residue S396A tau mutant (tau S39A transfected n = 7, untransfected n = 6). 613 
(d) CORT impairs LTP in neurons expressing tau S404A (tau S404A transfected n = 614 
5, untransfected n = 5). (e) The tau S/T 199/202/205A mutant was unable to prevent 615 
inhibition of LTP by CORT (tau S/T 199/202/205A transfected n = 6, untransfected n 616 
= 5). 2Hz stimulation indicated by black rectangles. All bars and circles represent the 617 
mean ± SEM. Statistical significance was determined by unpaired t-test.  618 
